Reversion of multidrug resistance by co-encapsulation of doxorubicin and curcumin in chitosan/poly(butyl cyanoacrylate) nanoparticles

Reversion of multidrug resistance by co-encapsulation of doxorubicin and curcumin in... Article history: Co-encapsulated doxorubicin (DOX) and curcumin (CUR) in poly(butyl cyanoacrylate) nanoparti- Received 4 November 2011 cles (PBCA-NPs) were prepared with emulsion polymerization and interfacial polymerization. The Received in revised form mean particle size and mean zeta potential of CUR–DOX–PBCA-NPs were 133 ± 5.34 nm in diam- 27 December 2011 eter and +32.23 ± 4.56 mV, respectively. The entrapment efficiencies of doxorubicin and curcumin Accepted 9 January 2012 were 49.98 ± 3.32% and 94.52 ± 3.14%, respectively. Anticancer activities and reversal efficacy of the Available online 17 January 2012 formulations and various combination approaches were assessed using 3-[4,5-dimethylthiazol-2-yl] 2,5- diphenyltetrazolium bromide assay and western blotting. The results showed that the dual-agent loaded Keywords: PBCA-NPs system had the similar cytotoxicity to co-administration of two single-agent loaded PBCA-NPs Curcumin (DOX–PBCA-NPs + CUR–PBCA-NPs), which was slightly higher than that of the free drug combination Doxorubicin (DOX + CUR) and one free drug/another agent loaded PBCA-NPs combination (DOX + CUR–PBCA-NPs or Poly(butyl cyanoacrylate) nanoparticles Multidrug resistance CUR + DOX–PBCA-NPs). The simultaneous administration of doxorubicin and curcumin achieved the highest reversal efficacy and down-regulation of P-glycoprotein in MCF-7/ADR cell lines, an MCF-7 breast carcer cell line resistant to adriamycin. Multidrug resistance can be enhanced http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png International Journal of Pharmaceutics Elsevier

Reversion of multidrug resistance by co-encapsulation of doxorubicin and curcumin in chitosan/poly(butyl cyanoacrylate) nanoparticles

Loading next page...
 
/lp/elsevier/reversion-of-multidrug-resistance-by-co-encapsulation-of-doxorubicin-q0G1ZeKmlC
Publisher
Elsevier
Copyright
Copyright © 2012 Elsevier B.V.
ISSN
0378-5173
D.O.I.
10.1016/j.ijpharm.2012.01.020
Publisher site
See Article on Publisher Site

Abstract

Article history: Co-encapsulated doxorubicin (DOX) and curcumin (CUR) in poly(butyl cyanoacrylate) nanoparti- Received 4 November 2011 cles (PBCA-NPs) were prepared with emulsion polymerization and interfacial polymerization. The Received in revised form mean particle size and mean zeta potential of CUR–DOX–PBCA-NPs were 133 ± 5.34 nm in diam- 27 December 2011 eter and +32.23 ± 4.56 mV, respectively. The entrapment efficiencies of doxorubicin and curcumin Accepted 9 January 2012 were 49.98 ± 3.32% and 94.52 ± 3.14%, respectively. Anticancer activities and reversal efficacy of the Available online 17 January 2012 formulations and various combination approaches were assessed using 3-[4,5-dimethylthiazol-2-yl] 2,5- diphenyltetrazolium bromide assay and western blotting. The results showed that the dual-agent loaded Keywords: PBCA-NPs system had the similar cytotoxicity to co-administration of two single-agent loaded PBCA-NPs Curcumin (DOX–PBCA-NPs + CUR–PBCA-NPs), which was slightly higher than that of the free drug combination Doxorubicin (DOX + CUR) and one free drug/another agent loaded PBCA-NPs combination (DOX + CUR–PBCA-NPs or Poly(butyl cyanoacrylate) nanoparticles Multidrug resistance CUR + DOX–PBCA-NPs). The simultaneous administration of doxorubicin and curcumin achieved the highest reversal efficacy and down-regulation of P-glycoprotein in MCF-7/ADR cell lines, an MCF-7 breast carcer cell line resistant to adriamycin. Multidrug resistance can be enhanced

Journal

International Journal of PharmaceuticsElsevier

Published: Apr 15, 2012

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off